Melanoma Stages and Prognosis: What They Mean for You

Melanoma, the most serious form of skin cancer, is less common than non-melanoma skin cancer but more dangerous. The reason is its ability to spread early, through the lymphatic system and the bloodstream, to other parts of the body. That is why the question of how far the disease has progressed matters so much. Doctors capture this in the idea of a stage. A stage describes how deeply a melanoma has grown into the skin and whether it has already reached lymph nodes or other organs. This classification guides which treatment makes sense and how the outlook should be judged. Put simply: the earlier a melanoma is found, and the thinner it still is, the better the chances of cure tend to be. An honest framing matters from the start. Figures on stages and survival are averages drawn from large groups of patients. They say something about the disease in general, but little about any one person. This article explains the stages and what they mean, so you can make better sense of findings and conversations with your doctor. It is not a substitute for medical advice.

Staging is based worldwide on the TNM system. The three letters stand for the three questions that determine how far a melanoma has spread. T describes the tumour itself, above all its thickness. N stands for the lymph nodes and shows whether nearby nodes are affected. M stands for distant metastases, that is, deposits in organs further away. Combining these three pieces of information gives the overall stage, which runs from 0 to IV. For melanoma, tumour thickness carries particular weight. It is called the Breslow thickness, after the pathologist Alexander Breslow, and is measured in millimetres, from the topmost to the deepest part of the tumour. Pathologists also note whether the surface of the tumour has broken open, known as ulceration, which makes the outlook less favourable. To determine the N stage, thicker but still localised melanomas are often assessed with a sentinel lymph node biopsy. The first lymph node in the drainage area of the tumour is removed and examined. If it is free of tumour cells, spread to further nodes is unlikely. This test mainly serves to classify the disease accurately and to help plan further treatment.

Stage 0 refers to melanoma in situ. Here the changed cells are still confined to the uppermost layer of skin and have not yet broken through into the deeper layers. At this stage the tumour cannot spread. Removed completely, it is considered highly curable. In stages I and II the melanoma has grown into the depth, that is, it is invasive, but has reached neither lymph nodes nor other organs. This is a localised melanoma. The difference between stage I and stage II lies mainly in tumour thickness and in whether the surface has broken open. Thinner melanomas without ulceration fall into stage I, thicker or ulcerated ones into stage II. In stage III the melanoma has reached the nearby lymph nodes, or small deposits have formed in the area around the original tumour, known as satellite or in-transit metastases. More distant organs are not yet affected. Stage IV, finally, describes a melanoma that has formed distant metastases, for example in skin further away, in distant lymph nodes or in internal organs such as the lungs, liver, bone or brain.

Of all the features of a melanoma, the Breslow thickness carries the greatest weight for the outlook. The rule of thumb is simple: the thinner a melanoma is when it is removed, the lower the chance that cells have already spread. A very thin melanoma therefore usually has an excellent outlook, while with increasing thickness the risk of recurrence and spread rises. A second important factor is ulceration, meaning that the surface of the tumour has broken open under the microscope. An ulcerated melanoma is classed less favourably than one of the same thickness without ulceration. The number of cell divisions in the tumour tissue, the mitotic rate, and involvement of the sentinel lymph node also feed into the assessment. These features explain why two people with the seemingly same diagnosis of melanoma can have very different outlooks. It is not the name of the disease that decides the prognosis, but the interplay of these fine tissue details that the pathologist determines under the microscope. That is why every assessment begins with the complete removal and examination of the suspicious mole.

When people talk about the chances of cure, specialists often use the five-year survival rate. It indicates what share of people with a particular stage are still alive five years after diagnosis, compared with people without the disease. It is a statistical measure, not a verdict on any individual course. For melanoma the figures paint a clear picture. According to the NHS and other cancer organisations, melanoma found early, while still localised, has a very good outlook, with a high five-year survival rate. As the stage advances, with lymph nodes involved or distant metastases present, the average survival rates fall. This gradient is the heart of why early detection is emphasised so strongly. At the same time, these very figures should be read with care. They reflect large groups and often come from a time when newer treatments were not yet available. The individual course depends on many factors and cannot be read off a percentage. Anyone who has received a diagnosis is best discussing their personal outlook with the treating team, who know all the findings.

For melanomas caught early, treatment is usually straightforward. The tumour is cut out with a safety margin. In many cases that is all that is needed, followed by regular checks. Depending on the thickness of the melanoma, the sentinel lymph node may also be examined to confirm the staging. For advanced melanomas the options have widened noticeably in recent years. Modern immunotherapies help the body's own defences to recognise and attack tumour cells. For melanomas with certain genetic changes, targeted drugs are added that act specifically on the tumour cells. Cancer organisations note that these approaches have changed the treatment of advanced melanoma. For those affected this means one thing above all: even a diagnosis at a higher stage is judged differently today than a few years ago. Which therapy is suitable in each case depends on the stage, the tissue features and the personal situation. That decision is always made by a specialist team, often in a tumour board.

The most important message from staging is this: the stage at diagnosis is the factor you can most readily influence. Noticing changes to the skin early and having them checked shifts the odds clearly in your favour. A melanoma found at stage 0 or I starts from a very different position than one that comes to light late. Early detection includes examining your own skin regularly, ideally in good light and with a mirror for areas that are hard to see. The ABCDE rule helps to judge suspicious moles: asymmetry, an irregular border, several colours, a larger diameter and, above all, change over time. Getting to know your own skin makes new or changing spots easier to notice. A digital tool like DermCheck can give you a first orientation. You upload a photo of a suspicious area of skin and receive an AI-based assessment of whether a medical check appears advisable. We value honesty here: such an initial assessment can sharpen your sense of your own risk and lower the barrier to seeing a doctor. It does not replace a diagnosis, let alone a staging.

This article is for general information and health education only. It explains how melanoma is staged and what the stages mean for the outlook, but does not replace medical advice, diagnosis or treatment. Staging a melanoma and judging the chances of cure are medical tasks that require examination of the tissue and a view of the whole person. If you notice a change in your skin, are unsure or have received a diagnosis, please see a dermatologist or a cancer specialist.